HNHannah Nam

Hannah Nam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hannah Nam has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    L2 β-lactamase contributes to ceftolozane-tazobactam resistance in Pseudomonas aeruginosa

    by Preeti Garai, Sophia H. Nozick, Caroline C. Jozefczyk, Hannah Nam, J. Nicholas O’DOnnell, Egon A. Ozer, Alan R. Hauser, Nathaniel J. Rhodes

    The prevalence of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low, but novel mechanisms of C/T resistance are of concern. Herein, we describe a novel P. aeruginosa genotype associated with high-level C/T resistance (>256/4 µg/mL) in a single patient. Whole-genome sequencing of the isolate was compared to that of a susceptible isolate cultured from the same patient 2 months earlier. Analysis of the sequences revealed two different P. aeruginosa high-risk clones: sequence type (ST)111 followed by ST235. The C/T-resistant ST235 isolate contained five copies of a genetic element composed of an L2 β-lactamase gene ( bla L2 ) and a truncated ampR L2 transcriptional regulator gene, which are commonly found together in Stenotrophomonas maltophilia strains and have not been reported to mediate resistance to C/T. Comparative genomic analysis with other P. aeruginosa isolates failed to identify alternative explanations for the observed C/T resistance. We found that exogenous expression of bla L2 increased C/T minimum inhibitory concentrations (MICs) in genetically distinct P. aeruginosa strains. A screen of our archived isolates identified two P. aeruginosa clinical isolates, PS2045 and PS2046, with one and two copies, respectively, of the genetic element containing bla L2 and truncated ampR L2 . Interestingly, disruption of the gene bla L2 but not the truncated ampR L2 in PS2045 led to a decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa partially mediated by an L2 β-lactamase independently of its canonical regulator, AmpR L2 .

  • Vaccination and safe living strategies for solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

    by Deepali Kumar, Robin Avery, Lara Danziger-Isakov, Victoria G. Hall, Benjamin Hanisch, Courtney E. Harris, Olivia S. Kates, Hannah H. Nam, Robert J. Rolfe, Camille N. Kotton


  • Open Access

    A novel mechanism of ceftolozane-tazobactam resistance in Pseudomonas aeruginosa mediated by L2 β-lactamase

    by Preeti Garai, Sophia H. Nozick, Caroline C. Jozefczyk, Hannah Nam, J. Nicholas O’DOnnell, Egon A. Ozer, Alan R. Hauser, Nathaniel J. Rhodes

    The prevalance of non-susceptibility to ceftolozane-tazobactam (C/T) among Pseudomonas aeruginosa remains low but novel mechanisms of C/T resistance are of concern. Herein, we describe a novel Pseudomonas aeruginosa genotype associated with high-level C/T resistance (>256/4 µg/mL) in a single patient. Whole genome sequencing of the isolate was compared to that of a susceptible isolate cultured from the same patient two months earlier. Analysis of the sequences revealed two different P. aeruginosa high-risk clones: ST111 followed by ST235. The C/T-resistant ST235 isolate contained five copies of a genetic element comprised of an L2 β-lactamase gene ( bla L2 ) and a truncated ampR L2 transcriptional regulator gene, which are commonly found together in Stenotrophomonas maltophilia strains and have not been reported to mediate resistance to C/T. Comparative genomic analysis with other P. aeruginosa isolates failed to identify alternative explanations for the observed C/T resistance. We found that exogenous expression of bla L2 modestly increased C/T MICs in genetically distinct P. aeruginosa strains. A screen of our archived isolates identified two P. aeruginosa clinical isolates, PS2045 and PS2046, with one and two copies, respectively, of the genetic element containing bla L2 and truncated ampR L2 . Interestingly, disruption of the gene bla L2 but not the truncated ampR L2 in PS2045 led to a significant decrease in C/T MIC. Thus, we report a novel mechanism of C/T resistance in P. aeruginosa mediated by an L2 β-lactamase independently of its canonical regulator AmpR L2 .

  • Open Access

    Persistent Impairment in Immune Reconstitution and Worse Survival Outcomes in Allogeneic Stem Cell Transplantation Patients with Early Coronavirus Disease 2019 Infection

    by Benjamin J. Lee, Pongthep Vittayawacharin, Shawn P. Griffin, Jean Doh, Hannah H. Nam, Deepa Jeyakumar, Emily Blodget, Piyanuch Kongtim, Stefan O. Ciurea


  • Open Access

    The burden of RSV, hMPV, and PIV amongst hospitalized adults in the United States from 2016 to 2019

    by Ajay Bhasin, David C. Nguyen, Benjamin J. Briggs, Hannah H. Nam

    Background: Respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus (PIV) hospitalize many people yearly. Though severe lower respiratory tract disease has been described in children, the elderly, and the immunocompromised, there is a gap in our understanding of RSV, hMPV, and PIV in hospitalized adults. We sought to evaluate the association of RSV, hMPV, and PIV with severe respiratory disease requiring noninvasive or mechanical ventilation and death in hospitalized adults in the United States.Methods: We conducted a retrospective, pooled, cross‐sectional study of general medicine hospitalizations in the United States from 2016 to 2019 using the National Inpatient Sample published by the Agency for Healthcare Quality and Research. We used multivariable Poisson regression to estimate the likelihood of severe respiratory disease or death. We used linear regression to estimate the mean difference in length of stay for those hospitalized with and without a respiratory virus.Results: We found that RSV (incidence rate ratio [IRR]: 1.68, 95% confidence interval [CI]: 1.61–1.74, p < .001), hMPV (IRR: 1.82, 95% CI: 1.71–1.93, p < .001), and PIV (IRR: 1.81, 95% CI: 1.68–1.94, p < .001) were independently associated with severe respiratory disease, even after adjustment. Additionally, we found the presence of a respiratory virus prolonged hospitalizations by (0.79 ± 0.27 days, p < .003) for RSV, (0.88 ± 0.28 days, p < .002) for hMPV, and (1.43 ± 0.30 days, p < .001) for PIV.Conclusions: RSV, hMPV, and PIV have a significant burden on hospitalized adults, even without classic risk factors.


  • Open Access

    Can Sociodemographic Factors be Used to Help Predict Outcomes in Charcot Neuroarthropathy?

    by Brandon J. Martinazzi, Kirsten N. Mansfield, Kelly Dopke, Anna Ptasinski, Chris M. Stauch, Zachary Koroneos, Hannah Nam, Gregory Kirchner, Michael C. Aynardi

    Category: Diabetes; Other Introduction/Purpose: The diabetic Charcot foot, or Charcot neuroarthropathy, is a devastating condition that arises secondary to longstanding diabetes, peripheral neuropathy, and trauma. One of the many challenges associated with the Charcot patient is the lack of data exploring factors that may predict long-term outcomes. Therefore, the purpose of this study was to evaluate how certain sociodemographic factors may influence mortality and the need to undergo lower extremity amputation in patients with Charcot. Methods: Following institutional board approval, all patients from 2015-2021 with a diagnosis of Charcot Foot were queried using hospital electronic medical records. Demographics collected included sex, age, race, and insurance coverage. Outcomes recorded were the need to undergo major amputation and mortality rate. Statistical analysis was then run to determine if sex, age, race, and insurance coverage was associated with increased risk of needing a major amputation or death. Results: From 2015-2021, 80 Charcot patients with a mean age of 60 (Range, 84-32) were identified. Of these patients, 58 were male, 26 were female, 71 were white, 3 were African American, and 6 were identified as other. In our cohort, 47 patients had government funded insurance and 33 had private insurance. Amputation occurred in 22 patients and death in 15. Government funded insurance (RR: 9.8, 95% CI:1.4-71.1, P = 0.0236) and age over 65 was associated with an increased risk of death (RR: 2.5, 95% CI: 1.02 to 6.17; P = 0.044). No statistically significant increased risk of death or amputation was found in white, African American, male, or female patients. Government insurance was also not associated with an increased risk for amputation (Table 1). Conclusion: Charcot Neuroarthropathy is associated with high rates of morbidity and mortality. In our cohort, there was an increased risk of mortality in patients with government funded insurance and patients over the age of 65. Further investigation exploring the role of sociodemographic factors is warranted.

  • Open Access

    Few Randomized Controlled Trials in Foot and Ankle Orthopaedics Include Sociodemographic Patient Data

    by Brandon J. Martinazzi, Gregory Kirchner, Hannah Nam, Kirsten N. Mansfield, Kelly Dopke, Anna Ptasinski, Vincenzo Bonaddio, Zachary Koroneos, Michael C. Aynardi

    Category: Other Introduction/Purpose: Social determinants of health play a major role in patient care. Factors such as race, education, and income have all been shown to impact patient outcomes in orthopaedic surgery. While retrospective studies are often limited by data availability, prospective randomized controlled trials (RCTs) are able to select their own patient demographics to be included in their analyses. However, the representation of sociodemographic data within RCTs regarding foot and ankle surgery is undefined. Therefore, the purpose of this study was to determine the incidence of sociodemographic data being reported in contemporary foot and ankle RCTs. Methods: RCTs within the PubMed database from 2016-2021 were searched using the search term 'Foot and Ankle Surgery.' Each article's journal of publication, year of publication, and outcome of interest were recorded. Articles were separated into the following outcomes of interest: Infection prevention, pain control, surgical outcomes, and non-operative outcomes. The full text of each article was reviewed to identify sociodemographic variables within the results or tables versus any part of the article (i.e., results or otherwise). Sociodemographic variables collected were race, ethnicity, insurance status, income, work status, and education. We then used the Fisher exact test to compare inclusion of sociodemographic data by journal, year, and outcome type. Results: A total of 34 studies across 15 different journals were included in our analysis. Of the 34 studies, 12 were grouped into operative outcomes, 11 into pain control, 7 into non-operative outcomes, and 4 into infection prevention. Race was reported in the results in 2 studies (5.9%), ethnicity in 1 (2.9%), insurance status in 0, income in 0, work status in 1 (2.9%) and education in 1 (2.9%). In any section other than the results, race was reported in 3 studies (8.8%), ethnicity in 1 (2.9%), insurance status in 3 (8.8%), income in 4 (11.8%), work status in 2 (5.9%), and education in 1 (2.9%). There was no difference found when comparing sociodemographic data to journal (p=0.127), year of publication (p=0.495), or outcome studies (p=0.439). Conclusion: The overall rate of sociodemographic data reported in foot and ankle RCTs is low. There was no difference in the reporting of sociodemographic data between journal, year of publication, or outcome of study.

  • Open Access

    Incidence of Venous Thromboembolism Following TAA: Does Chemoprophylaxis Work?

    by Brandon J. Martinazzi, Hannah Nam, Kelly Dopke, Kirsten N. Mansfield, Zachary Koroneos, Anna Ptasinski, Kristen Manto, Gregory Kirchner, Michael C. Aynardi

    Category: Ankle Arthritis; Ankle; Other Introduction/Purpose: Venous thromboembolism is a devastating and costly complication following TAA. The true incidence of VTE is unknown and the decision to prescribe chemoprophylaxis in foot and ankle surgery continues to be debated. At our institution, all patients receive a four-week course of chemoprophylaxis following TAA. The purpose of this study was to evaluate the incidence of VTE at our institution in patients receiving routine chemoprophylaxis. Methods: Following institutional board approval, a retrospective chart review was conducted for all patients that underwent TAA from 2018-2021 by a single surgeon. Patients were followed from the time of surgery to their six-week follow-up. Demographics and the type of chemoprophylaxis was recorded. For comparison, a large online database was queried using ICD and CTP codes in order to determine the incidence of VTE at 2 week and 6 weeks postoperatively for patients that underwent TAA and did not receive any form of chemoprophylaxis. Results: At our institution, from 2018-2021, 56 patients underwent TAA. The mean age of our cohort was 60.9 (Range, 56-83). In our cohort, 31 patients were male, 25 were female, and the mean patient BMI was 33.8 (Range, 21-56.2). Of the 56 patients, 12 received aspirin (81 mg), 25 received aspirin (325 mg), 16 received enoxaparin (40 mg), 2 received apixaban (5 mg), and 1 received rivaroxaban (20 mg). The total incidence of VTE at 6 weeks was 0%. For comparison, using a large online database (from 2011- 2021), 1,463 patients underwent TAA and did not receive postoperative chemoprophylaxis. Of these patients, 13 (0.89%) developed a postoperative VTE at 6-weeks following surgery. Conclusion: At our institution, the rate of VTE at 6-weeks postoperatively was 0%. This was lower than a large online database rate (0.89%) in patients that did not receive chemoprophylaxis. Further investigation is needed.

  • Open Access

    Prophylaxis for the Prevention of PJI after TAA: Is It Economically Justifiable?

    by Brandon J. Martinazzi, Gregory Kirchner, Hannah Nam, Kelly Dopke, Kirsten N. Mansfield, Anna Ptasinski, Michael C. Aynardi

    Category: Ankle Arthritis; Ankle; Other Introduction/Purpose: Prosthetic joint infection (PJI) is a costly and potentially fatal complication in total ankle arthroplasty (TAA). Some surgeons will use intraoperative vancomycin powder or copiously irrigate the surgical site with Povidone-iodine to prevent this outcome. Additionally, many surgeons will prescribe a short course of postoperative antibiotics. However, the efficacy of such prophylaxis continues to be debated, and little is known about the cost-effectiveness of these agents. Therefore, the purpose of this study was to perform a 'break-even' analysis to determine the number of cases that could be performed while only preventing a single PJI and still breaking even on cost. Methods: The literature was searched to determine the rate of PJI and the mean cost of total ankle replacement. The prices of topical vancomycin powder and Povidone-iodine were obtained from our institution's purchasing records. An online drug database was then used to determine the cost of a 14 day twice daily course of Sulfamethoxazole/Trimethoprim (800/160 mg), Cephalexin (500 mg), and Amoxicillin/Potassium Clavulanate (875/125 mg). A break-even analysis was then performed to determine the absolute risk reduction (ARR) necessary to make a drug cost-effective. Using the ARR, we calculated the number of patients that would need to be treated with these agents to prevent a single PJI (NNT). Results: The price of intraoperative vancomycin powder was found to be $3.06 while povidone-iodine was found to cost $3.64. Sulfamethoxazole/Trimethoprim (800/160 mg), Cephalexin (500 mg), and Amoxicillin/Potassium Clavulanate (875/125 mg) were determined to cost $3.00, $3.64, and $14.51, respectively. At the prices obtained Vancomycin Powder, Povidone-iodine, Sulfamethoxazole/Trimethoprim, and Cephalexin were all cost-effective if the initial rate decreased by ARRs of 0.01%. Likewise, Amoxicillin/Potassium Clavulanate was cost-effective if the initial rate decreased by an ARR of 0.03%. Additional analyses run found that all drugs-maintained cost-effectiveness even if the initial rate of PJI was as low as 0.1%. Conclusion: PJI following TAA is devastating and costly. Despite the ongoing debate regarding the efficacy of prophylactic measures to reduce the risk of PJI in TAA, limited is known about their cost-effectiveness. Our study demonstrates that intraoperative vancomycin powder, povidone-iodine lavage, and multiple commonly prescribed antibiotics are all highly cost- effective to prevent PJI following TAA. We feel that a tailored approach to taking measures to reduce PJI with cost-effectiveness in mind is crucial to providing value-based care.

  • Open Access

    Hemoglobin A1C in Charcot: Can It Predict a BKA?

    by Brandon J. Martinazzi, Kristen Manto, Vincenzo Bonaddio, Gregory Kirchner, Hannah Nam, Michael C. Aynardi

    Category: Diabetes; Ankle; Trauma; Other Introduction/Purpose: Charcot Foot is a serious and potentially limb-threatening complication of longstanding diabetes, peripheral neuropathy, and trauma. One of the many challenges that surgeons face when treating the Charcot Foot is predicting long-term outcomes. Therefore, the purpose of this study was to determine if hemoglobin A1C level was associated with an increased risk of BKA in Charcot Foot patients. Methods: Following institutional board approval, all patients from 2015-2021 with a diagnosis of Charcot Foot were queried using hospital electronic medical records. Patients were separated into two groups. Group A consisted of patients with a diagnosis of Charcot and a hemoglobin A1C3 6.5%, while group B consisted of patients with a diagnosis of Charcot and hemoglobin A1C < 6.5%. Statistical analysis was then performed to determine the relative risk of a BKA in patients exposed to a hemoglobin A1C3 6.5%, compared to those with a hemoglobin A1C < 6.5%. Only patients with a documented A1C around the time of diagnosis were included. Results: From 2015 to 2021, 80 patients were diagnosed with Charcot Foot. Of these patients, 59 met our inclusion criteria. Of the 59 patients, 20.3% (12/59) went on to require a BKA and 79.6% (47/59) did not. In our cohort, 54.2% of patients had a hemoglobin A1C3 6.5% and 45.8% (27/59) had a hemoglobin A1C < 6.5%. The relative risk of BKA in patients with an A1C3 6.5% was 2.5 (95% CI: 0.76-8.4; p=0.13). Conclusion: Charcot Foot is a debilitating and potentially limb-threatening complication. While our results suggest an associated increased risk of BKA in patients with an A1C3 6.5%, there was no statistical significance found. As such, further investigation is needed.